Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale® system: A first evaluation in humans
Posted 11 februari 2026 in PreciesInhale® - Clinic
Arkiv: Publikationer
Potential of the in vitro dissolution method DissolvIt® to predict pharmacokinetic outcomes
Posted 10 december 2025 in DissolvIt® – Dissolution tests
Cell line-based in vitro models of normal and chronic bronchitis-like airway mucosa to study the toxic potential of aerosolized palladium nanoparticles
Posted 10 oktober 2024 in XposeALI® – Cell culture exposure
Using PreciseInhale for Controlled Volunteer Exposures with Aerosols Extracted from Clinical Inhalers
Posted 15 december 2022 in PreciseInhale® – in vivo exposure
Simulation lung dissolution – fast-tracking DPI development
Posted 15 december 2022 in DissolvIt® – Dissolution tests
Bioavailability of inhaled or ingested PFOA adsorbed to house dust
Posted 28 juni 2022 in PreciseInhale® – in vivo exposure
Development of Combining of Human Bronchial Mucosa Models with XposeALI® for Exposure of Air Pollution Nanoparticles
Posted 03 mars 2022 in XposeALI® – Cell culture exposure
Multi-cellular human bronchial models exposed to diesel exhaust particles: assessment of inflammation, oxidative stress and macrophage polarization
Posted 03 mars 2022 in XposeALI® – Cell culture exposure
Air-Liquid Interface: Relevant In Vitro Models for Investigating Air Pollutant-Induced Pulmonary Toxicity
Posted 03 mars 2022 in XposeALI® – Cell culture exposure
Inhalation Pharmacokinetics of a Respirable Formulation of a Selective PDE4 Inhibitor, CHF6001, in Three Exposure Models: Isolated Perfused Lung, Intratracheally Intubated, and Nose-Only Exposed Rat
Posted 01 mars 2022 in PreciseInhale® – Isolated Perfused Lung (IPL)
